| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
|
Nat Med
|
2012
|
5.44
|
|
2
|
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
|
Nat Rev Clin Oncol
|
2013
|
2.64
|
|
3
|
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
|
Lancet Oncol
|
2016
|
1.42
|
|
4
|
Adjuvant therapy for renal cell carcinoma: past, present, and future.
|
Oncologist
|
2014
|
1.11
|
|
5
|
Recent developments in the treatment of renal cell carcinoma.
|
Ther Adv Urol
|
2013
|
1.05
|
|
6
|
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.
|
World J Urol
|
2013
|
0.98
|
|
7
|
Sunitinib re-challenge in advanced renal-cell carcinoma.
|
Br J Cancer
|
2014
|
0.93
|
|
8
|
Antigen-specific vaccines for cancer treatment.
|
Hum Vaccin Immunother
|
2014
|
0.89
|
|
9
|
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
|
Nat Rev Urol
|
2016
|
0.84
|
|
10
|
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning.
|
Oncoimmunology
|
2014
|
0.84
|
|
11
|
Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma.
|
Hum Vaccin Immunother
|
2015
|
0.83
|
|
12
|
Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008.
|
Drug Des Devel Ther
|
2014
|
0.82
|
|
13
|
A new age for vaccine therapy in renal cell carcinoma.
|
Cancer J
|
2013
|
0.81
|
|
14
|
Comparing comparators: a look at control arms in kidney cancer studies over the years.
|
Br J Cancer
|
2014
|
0.81
|
|
15
|
Therapeutic challenges in renal cell carcinoma.
|
Am J Clin Exp Urol
|
2015
|
0.80
|
|
16
|
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.
|
J Int AIDS Soc
|
2015
|
0.78
|
|
17
|
Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.
|
Front Oncol
|
2013
|
0.78
|
|
18
|
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
|
Oncoimmunology
|
2015
|
0.77
|
|
19
|
Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
|
Semin Oncol
|
2015
|
0.77
|
|
20
|
Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances.
|
J Natl Compr Canc Netw
|
2013
|
0.77
|
|
21
|
New clinical advances in immunotherapy for the treatment of solid tumours.
|
Immunology
|
2015
|
0.76
|
|
22
|
An update on current management of advanced renal cell cancer, biomarkers, and future directions.
|
Ann Cancer Res
|
2015
|
0.76
|
|
23
|
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
|
Clin Genitourin Cancer
|
2012
|
0.75
|
|
24
|
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.
|
Immunotargets Ther
|
2014
|
0.75
|